Worthington Financial Partners LLC Purchases New Stake in Medpace Holdings, Inc. $MEDP

Worthington Financial Partners LLC acquired a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 1,927 shares of the company’s stock, valued at approximately $1,082,000.

A number of other institutional investors and hedge funds have also bought and sold shares of MEDP. Optiver Holding B.V. bought a new position in Medpace during the third quarter worth about $27,000. Geneos Wealth Management Inc. raised its stake in Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares in the last quarter. Steigerwald Gordon & Koch Inc. bought a new stake in Medpace in the 4th quarter valued at about $30,000. Elyxium Wealth LLC bought a new stake in Medpace in the 4th quarter valued at about $30,000. Finally, Quarry LP acquired a new position in shares of Medpace during the 3rd quarter worth approximately $35,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

Insider Activity at Medpace

In other news, General Counsel Stephen P. Ewald sold 16,349 shares of the firm’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the completion of the sale, the general counsel directly owned 20,343 shares of the company’s stock, valued at $9,154,350. This trade represents a 44.56% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 20.50% of the company’s stock.

Medpace Stock Performance

MEDP stock opened at $460.20 on Friday. Medpace Holdings, Inc. has a 12 month low of $301.90 and a 12 month high of $628.92. The firm has a 50-day moving average price of $452.12 and a 200-day moving average price of $499.49. The stock has a market capitalization of $13.14 billion, a P/E ratio of 28.93, a price-to-earnings-growth ratio of 2.33 and a beta of 1.18.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share for the quarter, topping analysts’ consensus estimates of $3.74 by $0.54. The firm had revenue of $706.60 million during the quarter, compared to the consensus estimate of $697.82 million. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The business’s revenue was up 26.5% compared to the same quarter last year. During the same period last year, the business posted $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, equities analysts predict that Medpace Holdings, Inc. will post 17.04 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently commented on MEDP. Barclays lowered their target price on shares of Medpace from $500.00 to $450.00 and set an “equal weight” rating on the stock in a report on Friday, April 24th. Royal Bank Of Canada cut their price target on Medpace from $522.00 to $484.00 and set an “outperform” rating for the company in a research note on Friday, April 24th. Robert W. Baird reduced their price target on Medpace from $565.00 to $477.00 and set an “outperform” rating on the stock in a research report on Friday, April 24th. Wall Street Zen lowered Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Finally, BMO Capital Markets dropped their price objective on Medpace from $460.00 to $400.00 and set a “market perform” rating for the company in a report on Friday, April 24th. Four investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $467.08.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.